260 related articles for article (PubMed ID: 12393541)
1. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
Cragg MS; Morgan SM; Chan HT; Morgan BP; Filatov AV; Johnson PW; French RR; Glennie MJ
Blood; 2003 Feb; 101(3):1045-52. PubMed ID: 12393541
[TBL] [Abstract][Full Text] [Related]
2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
3. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS; Glennie MJ
Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
[TBL] [Abstract][Full Text] [Related]
4. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
5. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.
Chan HT; Hughes D; French RR; Tutt AL; Walshe CA; Teeling JL; Glennie MJ; Cragg MS
Cancer Res; 2003 Sep; 63(17):5480-9. PubMed ID: 14500384
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ
Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969
[TBL] [Abstract][Full Text] [Related]
7. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
[TBL] [Abstract][Full Text] [Related]
8. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
Ghetie MA; Crank M; Kufert S; Pop I; Vitetta E
J Immunother; 2006; 29(5):536-44. PubMed ID: 16971809
[TBL] [Abstract][Full Text] [Related]
9. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
10. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope.
Uchiyama S; Suzuki Y; Otake K; Yokoyama M; Ohta M; Aikawa S; Komatsu M; Sawada T; Kagami Y; Morishima Y; Fukui K
Cancer Sci; 2010 Jan; 101(1):201-9. PubMed ID: 19930155
[TBL] [Abstract][Full Text] [Related]
11. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
12. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
13. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
14. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
Polyak MJ; Deans JP
Blood; 2002 May; 99(9):3256-62. PubMed ID: 11964291
[TBL] [Abstract][Full Text] [Related]
15. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
[TBL] [Abstract][Full Text] [Related]
16. The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.
Khademi F; Mohammadi P; Mostafaei A
Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):205-220. PubMed ID: 33904679
[TBL] [Abstract][Full Text] [Related]
17. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.
Janas E; Priest R; Wilde JI; White JH; Malhotra R
Clin Exp Immunol; 2005 Mar; 139(3):439-46. PubMed ID: 15730389
[TBL] [Abstract][Full Text] [Related]
18. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
[TBL] [Abstract][Full Text] [Related]
20. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
Meyer S; Evers M; Jansen JHM; Buijs J; Broek B; Reitsma SE; Moerer P; Amini M; Kretschmer A; Ten Broeke T; den Hartog MT; Rijke M; Klein C; Valerius T; Boross P; Leusen JHW
Br J Haematol; 2018 Mar; 180(6):808-820. PubMed ID: 29468712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
